Literature DB >> 15001692

In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging.

Luigi Aloj1, Corradina Caracò, Mariarosaria Panico, Antonella Zannetti, Silvana Del Vecchio, Diego Tesauro, Stefania De Luca, Claudio Arra, Carlo Pedone, Giancarlo Morelli, Marco Salvatore.   

Abstract

UNLABELLED: Regulatory peptides and their analogs are being extensively investigated as radiopharmaceuticals for cancer imaging and therapy. Receptors of the cholecystokinin family have been shown to be overexpressed in different types of neuroendocrine tumors. The purposes of this study were to evaluate the cholecystokinin octapeptide amide (CCK8) peptide tagged with a diethylenetriaminepentaacetic acid derivative (DTPAGlu) and to test whether a (111)In-labeled conjugate ((111)In-DTPAGlu-G-CCK8, a derivative containing the chelating agent DTPAGlu bound through a glycine linker at the N-terminal end of the bioactive peptide CCK8) is suitable for cholecystokinin-B receptor (CCKBR) imaging.
METHODS: CCK8 was synthesized by solid-phase techniques and covalently coupled to DTPAGlu through a glycine linker at its amino terminus. The compound was labeled with (111)In. The radiochemical purity and stability of the compound were assessed by chromatographic methods. NIH-3T3 and A431 cells overexpressing CCKBR were used to characterize the in vitro properties of the compound. Nude mice bearing control and CCKBR-overexpressing A431 xenografts were used as an in vivo model.
RESULTS: DTPAGlu-G-CCK8 showed rapid and efficient labeling with (111)In. The radiolabeled conjugate showed specific binding to both cell lines overexpressing CCKBR. Binding was saturable, with a dissociation constant of approximately 20 nmol/L in both cell systems. Both cell lines showed internalization of the ligand after interaction with the receptor. Biodistribution studies showed rapid localization of (111)In-DTPAGlu-G-CCK8 on CCKBR-overexpressing A431 xenografts that was severalfold higher than that on control tumors at all time points tested. Unbound activity showed rapid clearance of over 80% through the kidneys by 30 min after injection. The labeled peptide conjugate was very stable in serum but showed a rapid breakdown after injection. Incubation with kidney homogenates suggested that most breakdown occurred in the kidneys, favoring the clearance of unbound activity.
CONCLUSION: Our findings indicate that the in vitro and in vivo characteristics of (111)In-DTPAGlu-G-CCK8 are favorable for CCKBR imaging, as the peptide shows high-affinity binding to the receptor, is internalized in CCKBR-expressing cells, and shows avid uptake in CCKBR-overexpressing xenografts, with rapid clearance of unbound radioactivity through the kidneys. Furthermore, the ease of synthesis, high labeling efficiency, and chemical stability of DTPAGlu make this chelating moiety an ideal candidate for widespread use in peptide radiolabeling for nuclear medicine applications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001692

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  33 in total

1.  DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.

Authors:  Maximilian Klingler; Dominik Summer; Christine Rangger; Roland Haubner; Julie Foster; Jane Sosabowski; Clemens Decristoforo; Irene Virgolini; Elisabeth von Guggenberg
Journal:  J Nucl Med       Date:  2018-12-07       Impact factor: 10.057

Review 2.  Peptides and peptide hormones for molecular imaging and disease diagnosis.

Authors:  Seulki Lee; Jin Xie; Xiaoyuan Chen
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.

Authors:  Luigi Aloj; Michela Aurilio; Valentina Rinaldi; Laura D'ambrosio; Diego Tesauro; Petra Kolenc Peitl; Theodosia Maina; Rosalba Mansi; Elisabeth von Guggenberg; Lieke Joosten; Jane K Sosabowski; Wouter A P Breeman; Erik De Blois; Stuart Koelewijn; Marleen Melis; Beatrice Waser; Karin Beetschen; Jean Claude Reubi; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-20       Impact factor: 9.236

4.  Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607.

Authors:  Meltem Ocak; Anna Helbok; Christine Rangger; Petra Kolenc Peitl; Berthold A Nock; Giancarlo Morelli; Annemarie Eek; Jane K Sosabowski; Wout A P Breeman; Jean Claude Reubi; Clemens Decristoforo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-29       Impact factor: 9.236

5.  Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours.

Authors:  Stephan Good; Martin A Walter; Beatrice Waser; Xuejuan Wang; Jan Müller-Brand; Martin P Béhé; Jean-Claude Reubi; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-29       Impact factor: 9.236

Review 6.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

7.  Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy.

Authors:  Stephen J Mather; Andrew J McKenzie; Jane K Sosabowski; Teresa M Morris; David Ellison; Susan A Watson
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

Review 8.  Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions.

Authors:  Maximilian Klingler; Anton Amadeus Hörmann; Elisabeth Von Guggenberg
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

9.  1,5-Disubstituted 1,2,3-Triazoles as Amide Bond Isosteres Yield Novel Tumor-Targeting Minigastrin Analogs.

Authors:  Nathalie M Grob; Roger Schibli; Martin Béhé; Ibai E Valverde; Thomas L Mindt
Journal:  ACS Med Chem Lett       Date:  2021-03-16       Impact factor: 4.345

10.  177Lu Labeled Cyclic Minigastrin Analogues with Therapeutic Activity in CCK2R Expressing Tumors: Preclinical Evaluation of a Kit Formulation.

Authors:  Christine Rangger; Maximilian Klingler; Lajos Balogh; Zita Pöstényi; Andras Polyak; Dariusz Pawlak; Renata Mikołajczak; Elisabeth von Guggenberg
Journal:  Mol Pharm       Date:  2017-08-07       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.